Search
Lulizumab pegol
go.drugbank.com/drugs/DB15441InvestigationalLulizumab pegol is under investigation in clinical trial NCT02843659 (Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome).
Bemegride
go.drugbank.com/drugs/DB13740ExperimentalBemegride is a CNS stimulant that is used to induce convulsions in experimental animals. It has also been used as a respiratory stimulant and in the treatment of barbiturate overdose.
Spaglumic acid
go.drugbank.com/drugs/DB08835InvestigationalSpaglumic acid is the β-aspartyl isoform of N-Acetyl-l-aspartylglutamate (isospaglumic Acid is N-(N-Acetyl-l-α-aspartyl)-l-glutamic acid). In eye drops, spaglumic acid is either a magnesium or sodium salt of N-Acetyl-l-aspartylglutamate....
N-(4-carbamimidoylbenzyl)-1-(3-phenylpropanoyl)-L-prolinamide
go.drugbank.com/drugs/DB06942ExperimentalThis compound belongs to the alpha amino acid amides. These are amide derivatives of alpha amino acids. This medication targets the protein prothrombin.
Atipamezole
go.drugbank.com/drugs/DB11481InvestigationalVet approvedAtipamezole is a synthetic α2 adrenoceptor antagonistused to reverse the sedative and analgesic effects of dexmedetomidine and medetomidine in dogs.
Simurosertib
go.drugbank.com/drugs/DB16330InvestigationalSimurosertib is under investigation in clinical trial NCT03261947 (A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal
BMS-986104
go.drugbank.com/drugs/DB15214InvestigationalBMS-986104 is under investigation in clinical trial NCT02211469 (A Randomized, Placebo-Controlled, Double-Blind, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics
AG0301-COVID19
go.drugbank.com/drugs/DB15856InvestigationalAG0301-COVID19 is a vaccine candidate developed by AnGes Inc. and Osaka University.
OPC-28326
go.drugbank.com/drugs/DB05461ExperimentalAt low doses, OPC 28326 selectively vasodilates the femoral arterial bed due to its inhibitory action at alpha-2-adrenoceptors while having minimal action on systemic blood pressure, heart rate and coronary
Galegenimab
go.drugbank.com/drugs/DB18860InvestigationalGalegenimab is under investigation in clinical trial NCT03972709 (A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to